Full GMP-Compliant Validation of Bone Marrow-Derived Human CD133⁺ Cells as Advanced Therapy Medicinal Product for Refractory Ischemic Cardiomyopathy

Table 1

Purity and viability of CD133⁺ cells (%) obtained in 8 batches of ATMP-CD133.

Batch #	% CD133^+		Cell viability
	Starting material	Final product (purity)	Starting material	Final product
PTC-CD133-052	1.87	96.2	95.83%	96.03%
PTC-CD133-055	3.39	81.87	96.83%	97.70%
PTC-CD133-068	0.86	94.61	95.27%	99.87%
PTC-CD133-085	1.18	89.80	87.67%	99.91%
PTC-CD133-090	0.41	81.40	96.62%	99.75%
PTC-CD133-098	0.90	91.40	93.62%	99.95%
PTC-CD133-109	1.21	93.64	96.28%	99.97%
PTC-CD133-116	0.90	81.94	96.29%	99.86%
Mean	1.34	88.86	94.80%	99.13%
Standard deviation	0.93	6.21	3.06%	1.47%
Median	1.04	90.60	96.06%	99.87%
Minimum value	0.41	81.40	87.67%	96.03%
Maximum value	3.39	96.2	96.83%	99.97%